Asian Activities Report for September 30, 2011: Neon Energy (ASX:NEN) Sixth Well Successfully Brought Onstream in North San Ardo Oil Field, California

Sydney, Sep 30, 2011 AEST (ABN Newswire) - Neon Energy Limited (ASX:NEN) says today that the recently drilled Lombardi 19-27H development well in the North San Ardo oil field, onshore California, has been brought onstream, with a stabilised initial production rate of approximately 250 bopd. This is the Company's sixth successful acceleration well to date. Total production at the oil field is currently in the range of 650 bopd to 700 bopd, with sales pricing at over US$100 per barrel.

India Resources Limited (ASX:IRL) has signed a A$249M coal operations contract with Prism Cement Limited (BOM:500338) to develop and operate the first phase of Prism's Sial Ghoghri coal mine in India for over 30 years. The first phase of the mine development is expected to produce 9.06 million tonnes of coal.

Guildford Coal Limited (ASX:GUF) has upgraded its Exploration Targets at its Mongolian coal projects to 30Mt to 1.380Bt, comprising Exploration Targets of 0-700Mt at the South Gobi Project and 30Mt-680Mt at the Middle Gobi Project. The Company plans to continue the current drilling program at both Projects with a view to defining JORC compliant resources by the end of October 2011.

Tissue Therapies Limited (ASX:TIS) says today that commercial negotiations are proceeding very well and the Company expects to start the sales of VitroGro(R) for the treatment of chronic wounds in the UK and Europe during the second quarter of 2012. In addition, preparations for the FDA clinical trial of VitroGro(R) for the treatment of venous ulcers are almost complete, and patient recruitment for the trial is planned to start during December 2011.

Biotron Limited (ASX:BIT) has commenced a human trial of its lead HIV drug candidate, BIT225, to further demonstrate its ability to reduce HIV loads in HIV-infected reservoir cells. BIT225 has recorded encouraging data in previous trials in healthy volunteers and Hepatitis C virus-infected patients. The results of the current trial is expected in the first quarter of 2012.

Circadian Technologies Limited (ASX:CIR) has submitted an investigational new drug application to the FDA to initiate clinical studies of VGX-100. The first trial will involve the treatment of a variety of different cancer types in patients with late stage cancer.

Contact

Asia Business News Tel: +61-2-9247-4344 http://www.abnnewswire.net